In recent years, it has become increasingly clear that the extra-renal effects of aldosterone play an important role in the pathogenesis of cardiovascular disease. Stroke is one of the leading causes of death in the Western world, and MR (mineralocorticoid receptor) antagonism is a potential preventative therapy for patients at risk of both ischaemic and haemorrhagic strokes. This protective effect of MR antagonism appears to occur at the level of the cerebral vasculature and may be related to the expression and activation of the EGFR (epidermal growth factor receptor) and the degree of vessel wall collagen deposition.
Skip Nav Destination
Review Article| November 30 2007
Is the mineralocorticoid receptor a potential target for stroke prevention?
Jessica M. Osmond;
Christine' S. Rigsby;
Anne M. Dorrance
1Department of Physiology, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912, U.S.A.
Correspondence: Dr Anne M. Dorrance, at the present address: Department of Pharmacology/Toxicology, Michigan State University, East Lansing, MI 48824, U.S.A. (email firstname.lastname@example.org).
Search for other works by this author on:
- Views Icon Views
- Share Icon Share
Jessica M. Osmond, Christine' S. Rigsby, Anne M. Dorrance; Is the mineralocorticoid receptor a potential target for stroke prevention?. Clin Sci (Lond) 1 January 2008; 114 (1): 37–47. doi: https://doi.org/10.1042/CS20070155
Download citation file:
Don't already have an account? Register
Get Access To This Article
Buy This Article